Asarina Pharma AB (publ) Q3 Report 2021 released
Asarina Pharma CEO Peter Nordkild: “While we made progress in several areas during Q3 2021, it was frustrating for us that our phase IIa study in Tourette Syndrome was delayed. We now expect our first patients to be included in the Study in December.”FINANCIAL HIGHLIGHTS · Significant reduction in operating costs in Q3 · Cash position on 30 September 2021 (SEK 23.5 million) still expected to cover the Tourette study R&D HIGHLIGHTS · TOURETTE SYNDROME Following an administrative delay from Region Hovedstaden (the Capital Region of Denmark) we expect to receive final legal